Eric Richman | Source | CEO at Gain Therapeutics

Eric I. Richman began his career in venture capital at HealthCare Ventures and most recently was venture partner at Brace Pharma Capital, a life science venture capital firm. He also serves as an advisor to Broad Oak Capital, a life science private equity firm and as a Venture Partner at Allele Capital. Mr. Richman has also previously served as chief executive officer of Tyrogenex and PharmAthene, subsequently acquired by Altimmune.